Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
- PMID: 34416160
- DOI: 10.1016/S1470-2045(21)00422-8
Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
Conflict of interest statement
PR has received honoraria for lectures and participation in advisory meetings from Bristol Myers Squibb, Merck, MSD, Novartis, Pierre Fabre, and Sanofi; and honoraria for participation in advisory meetings from Blueprint Medicines and Philogen. PR is a member of the International Affairs Committee for the American Society of Clinical Oncology and a member of the board of directors for the Polish Society of Surgical Oncology.
Comment on
-
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.Lancet Oncol. 2021 Sep;22(9):1312-1321. doi: 10.1016/S1470-2045(21)00387-9. Epub 2021 Aug 17. Lancet Oncol. 2021. PMID: 34416158 Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical